Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
ZLAB · NASDAQ · Pharmaceutical Preparations
Zai Lab (ZLAB) · oqro.io/stocks/ZLAB · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$24.60−1.44 (−5.53%)
Close of Nov 13, 2026, vs Nov 12 · end-of-day, not a live quote
Yes. Insiders of Zai Lab (ZLAB) filed 1 open-market purchase in the last 90 days; the latest was filed on Nov 13, 2026.
Since 2021, Zai Lab insiders reported 7 open-market purchases and 274 sales on Forms 4 and 5, with purchases in 5 different years, most recently 2026.
No open-market sale by an insider of Zai Lab (ZLAB) was filed with the SEC in the last 90 days.
No trade in Zai Lab (ZLAB) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
+13.2% (+$2.87) from Nov 13, 2025 to Nov 13, 2026 · adjusted daily closes
Adjusted close went from $21.73 on Nov 13, 2025 to $24.60 on Nov 13, 2026 (+13.2%). Disclosed in this range: 1 insider trade, 0 pre-arranged insider sales, 0 Congress trades, and 4 13F position changes for 2 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Shanghai.
Last 12 months
+13.2%
Market value
–
S&P 500 +12.3% over the same dates. Prices adjusted for splits and dividends.
Short interest: 8.09M shares sold short, −8.5% vs the previous count, 6.7 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
$106M
−3.3% vs the same quarter a year earlier
Free cash flow, last 12 months
−$140M
This quarter −$64.7M, a year earlier −$33.9M
Net debt
—
Debt —, cash $608M, at Jun 30, 2026
Net income, last 12 months
−$188M
Operating profit covers interest -44.1x
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 5, 2026.
Revenue, fiscal 2025
$460M
+15.3% vs the year before
Net income, fiscal 2025
−$176M
A loss for the year
Shares outstanding
Not available
Reported per share class only, with no single total
Insider buying
First insider buy since Sep 2025Traded Nov 10 · filed 3 days later
Since the trade −6.9% · S&P 500 +0.6% · to Nov 13
Fund moves
Among this manager's largest new positions for Q1 2026. From a 13F filed May 15, 2026 covering holdings at Mar 31, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
From a 13F filed May 15, 2026 covering holdings at Mar 31, 2026 — a quarter-end snapshot, not a live trade.
Fund moves
4 tracked managers disclosed the same change for Q4 2025. From a 13F filed Feb 17, 2026 covering holdings at Dec 31, 2025 — a quarter-end snapshot, not a live trade.
Fund moves
4 tracked managers disclosed the same change for Q4 2025. From a 13F filed Feb 13, 2026 covering holdings at Dec 31, 2025 — a quarter-end snapshot, not a live trade.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Against the S&P 500 over the year
Since Nov 11, 2025, ZLAB is up 11.8% and the index fund is up 10.4%: 1 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much ZLAB moves
End-of-day prices. These figures describe the past year and say nothing about what comes next.
Insiders of Zai Lab reported 7 open-market purchases and 274 sales since 2021; purchases in 5 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $33K1×1 trade | — |
| 2025 | $289K1×1 trade | $25.8M51×51 trades |
| 2024 | $127K2×2 trades | $3.12M34×34 trades |
| 2023 | $254K2×2 trades | $995K4×4 trades |
| 2022 | — | $505K6×6 trades |
| 2021 | $285K1×1 trade | $134M179×179 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
3 active phase 3 trials and 1 active phase 2 trial led by this company, mostly in thyroid eye disease (ted), solid tumors, small-cell lung cancer. The ones with the nearest registered primary completion date still ahead:
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.
On the public record for Zai Lab over the 12 months to Nov 14, 2026: 4 clinical trials.
